Method of increasing testosterone and related steroid concentrations in women

• US 20030022877A1
• Filed: 05/21/2002
• Published: 01/30/2003
• Est. Priority Date: 08/30/2000
• Status: Abandoned Application

• Current Assignee: Robert E. Dudley
• Original Assignee: Robert E. Dudley
• Inventors: Dudley, Robert E.
• Application Number:
  US10/153,468
• Publication Number:
  US 20030022877A1
• Time in Patent Office: Days
• US Class Current: 514/177
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/12 Carboxylic acids; Salts or anhydrides thereof
• CPC Class Codes: A61K 47/14 Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00

Abstract

The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a testosterone deficient disorder, or the symptoms associated with, or related to a testosterone deficient disorder in a subject in need thereof. The present invention also relates to a method of administering a steroid in the testosterone synthetic pathway to a subject in need thereof. In addition, the methods, kits, combinations and compositions may be used in conjunction with other pharmaceutical agents effective at treating, preventing, or reducing the risk of developing a testosterone deficient disorder. The present invention also can also be used in conjunction with a pharmacologically effective amount of an estrogenic hormone. Furthermore, the methods, kits, combinations and compositions can be used in conjunction with a pharmacologically effective amount of another steroid or pharmaceutical agent that increases serum testosterone levels in a mammal.

Claims

1. A method of treating, preventing or reducing the risk of developing a testosterone-deficient disorder in a female subject in need thereof, comprising:

administering an amount of a composition to an area of skin of the subject, which delivers a therapeutically-effective amount of testosterone to the blood serum of the subject, wherein the composition comprises;

a. about 0.1% to about 10% testosterone, or a salt, ester, amide, enantiomer, isomer, tautomer, prodrug, or derivative thereof;

b. about 30% to about 98% alcohol selected from the group consisting of ethanol or isopropanol;

c. about 0.1% to about 5% isopropyl myristate;

d. about 0.1% to about 10% sodium hydroxide; and

e. about 0.1% to about 5% of a gelling agent;

wherein the percentages are on a weight to weight basis of the composition and the sum of components of the composition is about 100 weight %; and

the composition is capable of releasing the testosterone to the skin at a rate and duration that raises testosterone blood serum concentration to at least about 3 pg testosterone/ml blood serum within about 24 hours after administration.

2. The method of claim 1, wherein the composition comprises about 0.5% to about 1% testosterone.

3. The method of claim 1, wherein the composition comprises about 45% to about 90% alcohol.

4. The method of claim 1, wherein the composition comprises about 0.5% isopropyl myristate.

5. The method of claim 1, wherein the gelling agent is selected from the group consisting of polyacrylic acid and carboxymethylcellulose.

6. The method of claim 1, wherein the gelling agent is polyacrylic acid present in an amount of about 1% weight to weight of the composition.

7. The method of claim 1, wherein the composition comprises about 1% to about 3% sodium hydroxide.

8. The method of claim 1, wherein the composition weighs less than or equal to about 100 grams.

9. The method of claim 1, wherein the composition weighs about 1 grams to about 10 grams.

10. The method of claim 1, wherein the composition weighs about 2.5 grams to about 7.5 grams.

11. The method of claim 1, wherein the composition is a form of a gel.

12. The method of claim 1, wherein for each about 0.1 gram per day application of the composition to the skin, an increase of at least about 5 ng/dl in serum testosterone concentration results in the subject.

13. The method of claim 1, wherein the composition is provided to the subject for daily administration in about a 0.1 g to about a 10 g dose.

14. The method of claim 1, wherein the amount of the composition is a 0.44 g dose delivering about 0.44 mg to about 44 mg of testosterone to the skin.

15. The method of claim 1, wherein the amount of the composition is a 0.44 g dose delivering about 2.2 mg to about 4.4 mg of testosterone to the skin.

16. The method of claim 1, wherein the amount of the composition is a 1.32 g dose delivering about 1.32 mg to about 132 mg of testosterone to the skin.

17. The method of claim 1, wherein the amount of the composition is a 1.32 g dose delivering 6.6 mg to about 13.2 mg of testosterone to the skin.

18. The method of claim 1, wherein the composition is provided to the subject in one or more packets.

19. The method of claim 22, where in the packet comprises a polyethylene liner between the composition and inner surface of the packet.

20. The method of claim 1, wherein the composition is provided as a separate component to a kit.

21. The method of claim 1, wherein the composition is administered once, twice, or three times a day.

22. The method of claim 1, wherein the composition further comprises about 0.01% to about 69% of a therapeutic agent comprising an agent that inhibits the synthesis of the sex hormone binding globulin, a progesterone, a progestin, or an estrogenic hormone.

23. The method of claim 22, wherein the therapeutic agent comprises about 1% to about 10% of the composition.

24. The method of claim 22, wherein the therapeutic agent is progesterone.

25. The method of claim 24, wherein serum blood level of progesterone is raised to at least about 1 ng progesterone/ml blood serum within about 24 hours after administration.

26. The method of claim 22, wherein the therapeutic agent is estrogen.

27. The method of claim 26, wherein serum blood level of estrogen is raised to at least 60 pg estrogen/ml blood serum within about 24 hours after administration.

28. A method of treating, preventing or reducing the risk of developing a testosterone-deficient disorder in a female subject in need thereof, comprising:

(i) identifying a female subject having, or at risk of developing, a testosterone-deficient disorder;

(ii) administering an amount of a composition to an area of skin of the subject, which delivers a therapeutically-effective amount of testosterone to the blood serum of the subject such that the testosterone-deficient disorder or the risk of developing a testosterone-deficient disorder is reduced, wherein the composition comprises;

a. about 0.1% to about 10% testosterone, or a salt, ester, amide, enantiomer, isomer, tautomer, prodrug, or derivative thereof;

b. about 30% to about 98% alcohol selected from the group consisting of ethanol or isopropanol;

c. about 0.1% to about 5% isopropyl myristate;

d. about 0.1% to about 10% sodium hydroxide; and

e. about 0.1% to about 5% of a gelling agent;

wherein the percentages are on a weight to weight basis of the composition and the sum of components of the composition is about 100 weight %; and

the composition is capable of releasing the testosterone to the skin at a rate and duration that raises testosterone blood serum concentration to at least about 3 pg testosterone/ml blood serum within about 24 hours after administration.

29. A method of delivering a testosterone-deficient disorder effective amount of testosterone to blood serum of a female subject in need thereof, comprising:

contacting the skin of the subject with a composition comprising;

a. about 0.1% to about 10% testosterone, or a salt, ester, amide, enantiomer, isomer, tautomer, prodrug, or derivative thereof;

b. about 30% to about 98% alcohol selected from the group consisting of ethanol or isopropanol;

c. about 0.1% to about 5% isopropyl myristate;

d. about 0.1% to about 10% sodium hydroxide; and

e. about 0.1% to about 5% of a gelling agent;

wherein the percentages are on a weight to weight basis of the composition and the sum of components of the composition is about 100 weight %; and

the composition is capable of releasing the testosterone to the skin at a rate and duration that raises testosterone blood serum concentration to at least about 3 pg testosterone/ml blood serum within about 24 hours after administration.

30. A method for administering a testosterone-deficient disorder effective amount of testosterone to blood serum of a female subject in need thereof, the method comprising:

(i) providing a pharmaceutical composition comprising;

a. about 0.1% to about 10% testosterone, or a salt, ester, amide, enantiomer, isomer, tautomer, prodrug, or derivative thereof;

b. about 30% to about 98% alcohol selected from the group consisting of ethanol or isopropanol;

c. about 0.1% to about 5% isopropyl myristate;

d. about 0.1% to about 10% sodium hydroxide; and

e. about 0.1% to about 5% of a gelling agent; and

(ii) applying the composition to skin of the subject in an amount sufficient for the testosterone to reach the blood serum of the subject so as to achieve a serum concentration of at least 3 pg testosterone/ml blood serum within about 24 hours after administration;

wherein the percentages are on a weight to weight basis of the composition and the sum of components of the composition is about 100 weight %.